Aditxt, Inc. (NASDAQ: ADTX), an innovation-driven company focused on accelerating healthcare advancements, announced today that its majority-owned subsidiary, Pearsanta, Inc., has entered into a Market Development Collaboration Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM), a leader in women’s health. This partnership centers around Pearsanta’s blood-based diagnostic test for endometriosis, a chronic condition affecting approximately 190 million women worldwide, as reported by the World Health Organization.
The diagnostic tool, known as the Mitomic® Endometriosis Test (MET™), detects a unique deletion in mitochondrial DNA (mtDNA), a proprietary biomarker for endometriosis. Currently, no blood-based tests for endometriosis are validated in the U.S. or globally, making this a groundbreaking development.
Under the agreement, Pearsanta and Evofem will collaborate to create a comprehensive go-to-market strategy for the MET, targeting a U.S. launch in mid-2025. To date, over 300 endometriosis cases have been evaluated with MET, with 600 more planned for clinical validation.
This collaboration aligns with Evofem’s strategy to expand its portfolio of innovative women’s health products. Evofem currently offers a single-dose oral treatment for bacterial vaginosis and trichomoniasis, as well as a hormone-free contraceptive gel. The company’s long-term goal is to provide comprehensive healthcare solutions addressing prevention, diagnosis, and treatment in women’s sexual and reproductive health.
Christopher Mitton, President of Pearsanta, expressed confidence in the partnership, stating, “Evofem’s expertise in women’s health makes them the ideal partner for the U.S. launch of our Mitomic Endometriosis Test. Their industry knowledge and established relationships will be crucial in bringing this innovative diagnostic to market and exploring future applications of our mitochondrial DNA platform.”
Endometriosis has significant health implications, affecting more than just painful symptoms. Roughly 70% of women with endometriosis experience chronic pelvic pain, and nearly 50% face infertility challenges. The condition is also linked to other health concerns, such as irritable bowel syndrome and interstitial cystitis, and it can cause psychological stress, anxiety, depression, and a reduced quality of life.
Early diagnosis is key to effective medical or surgical intervention for endometriosis, yet no validated blood-based diagnostic tests currently exist. Pearsanta’s MET aims to fill this gap in healthcare.
Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt, emphasized the strategic value of the collaboration: “This partnership exemplifies the Aditxt platform’s ability to foster growth and bring high-impact innovations to market. By advancing Pearsanta’s Mitomic Endometriosis Test toward commercialization in 2025 and supporting Evofem’s goal of diversifying its product portfolio, we demonstrate how our platform empowers progress for both current and future subsidiaries.”
Saundra Pelletier, CEO of Evofem Biosciences, added, “With Pearsanta’s Mitomic Endometriosis Test, physicians will have a powerful tool to diagnose and improve the lives of women suffering from this chronic disease. We look forward to leveraging our strong relationships with OB/GYNs and healthcare providers to ensure the successful U.S. launch of this groundbreaking non-invasive diagnostic.
